Emerging Pathogens, Vaccine and Breakthrough Infection News and Medical Cases
No significant difference in hospitalization between immunized and non-immunized found for SARS-CoV-2 Beta variant
Get link
Facebook
X
Pinterest
Email
Other Apps
A study of vaccinated and unvaccinated residents of Bangladesh observed that ChAdOx1 could not prevent the new infection or severe COVID-19 disease outcome with single dose when infections were mostly caused by B.1.351 (the Beta) variants of SARS-CoV2.
About 39% (n = 42) of the respondents were infected after the COVID-19 vaccination. The first dose of ChAdOx1 nCoV-19 vaccine was received by 40 (37.0%) cases and both doses were completed by only 2 (2%) cases. The average duration between vaccination (partially or completely immunized) and COVID 19 diagnosis was 32 (±17) days.
The hospitalization rate of comorbid patients was 23.5% among the immunized and 24.1% among the nonimmunized groups. There was no significant difference in duration of hospitalization either (p=0.78).
Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh
Al-Emran HM, Hasan MS, Setu MA, Rahman MS, Alam AR, Sarkar SL, Islam MT, Islam MR, Rahman MM, Islam OK, Jahid IK. Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. Journal of Infection and Public Health. 2021 Dec 7.
Previously we presented case reports with oral side effects of COVID-19 vaccine due to mucocutaneous reactions. Trigeminal neuralgia (TN) could be another reason for oral manifestations, including severe tooth pain. A 45-year-old female was admitted to a research hospital with 3 days of facial and jaw pain, fatigue and toothache following the first dose of Pfizer-BioNtech vaccine against SARS-CoV-2. The features of the pain were unilateral, acute onset, and severe, on the lower right side of the face. It was triggering with brushing her teeth and putting on makeup. The case was considered as trigeminal neuralgia. Pregabalin failed to control the pain, while amoxicillin/clavulanic acid (despite normal X-rays) led to angioedema and worsening of her general condition. However, with steroid treatment, the patient eventually recovered. A 36-year-old woman was admitted to the Emergency Ward due to chronic pain attacks in the left side of her face. The pain appeared tw...
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine. Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes. There are ten published case reports about the newly diagnosed ulcerative colitis ...
In summer 2025, the Nimbus (NB.1.8.1) and Stratus (XFG) variants were competing for dominance (see previous post Nimbus and Stratus: Cloudy With a Chance of Covid ). By that point, earlier JN.1-descended variants such as LP.8.1 had already been largely displaced. That competition is now largely settled, with Stratus and its descendants firmly in the lead across most regions. As of early January 2026, Stratus (XFG) and its descendants dominate globally. In the U.S., sequencing and wastewater data show XFG making up 60–70% of cases, and when its sublineages (XFG.14.1, XFG.1, XFG.6) are included, the total reaches ~80% by late December. Nimbus has fallen sharply and now accounts for roughly 5% of sequenced cases. The new variant to watch is BA.3.2 nicknamed “Cicada”. Unlike recent variants that evolved incrementally from JN.1, BA.3.2 represents a larger evolutionary jump. It's a descendant of early Omicron BA.3, a lineage that largely disappeared in 2022. Cicada was designated by WHO...
Comments
Post a Comment